{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:29:54Z","timestamp":1782890994139,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the efficacy of angiotensin\u2010converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) vs calcium channel blockers (CCBs) on the progression of Corona Virus Disease 2019 (COVID\u201019) patients with hypertension in Wuhan. This retrospective single\u2010center case series analyzed COVID\u201019 patients with hypertension, treated with ACEIs\/ARBs or CCBs at the Tongji Hospital of Wuhan City, China from 25th January to 15th March 2020. After propensity score matching analysis, 76 patients were selected into two groups. Univariate and multivariable analyses were conducted to determine factors related to improvement measures and outcome measures by Cox proportional hazard regression models. Among 157 patients with confirmed COVID\u201019 combined hypertension, including 73 males and 84 females, a median age of 67.28\u2009\u00b1\u20099.11 vs 65.39\u2009\u00b1\u200910.85 years. A univariable analysis indicated that clinical classification, lymphocyte count, and interleukin\u20102 receptor were associated with a lengthened negative time of nucleic acid, with a significant difference between two groups (<jats:italic>P<\/jats:italic>\u2009=\u2009.036). Furthermore, we found no obvious difference in nucleic acid conversion time between ACEIs\/ARBs and CCBs groups (hazard ratio [HR]: 0.70; 95% confidence interval [CI]: [0.97, 3.38]; <jats:italic>P<\/jats:italic>\u2009=\u2009.18) in the multivariable analysis as well as chest computed tomography improved time (HR: 0.73; 95% CI [0.45, 1.2]; <jats:italic>P<\/jats:italic>\u2009=\u2009.87), and hospitalization time between ACEIs\/ARBs and CCBs groups (HR: 1.06; 95% CI [0.44, 1.1]; <jats:italic>P<\/jats:italic>\u2009=\u2009.83). Our study provided additional evidence of no obvious difference in progress and prognosis between ACEIs\/ACEIs and CCBs group, which may suggest ACEIs\/ARBs may have scarcely influence on increasing the clinical severe situations of COVID\u201019 patients with hypertension.<\/jats:p>","DOI":"10.1002\/jmv.26315","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T17:25:56Z","timestamp":1595265956000},"page":"854-862","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of ACEIs\/ARBs vs CCBs on the progression of COVID\u201019 patients with hypertension in Wuhan: A hospital\u2010based retrospective cohort study"],"prefix":"10.1002","volume":"93","author":[{"given":"Xiulan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliang","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of Xuanwu Hospital The First Clinical Medical College of Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of Xuanwu Hospital The First Clinical Medical College of Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1222","authenticated-orcid":false,"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science and Technology  Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Novel Coronavirus(2019\u2010nCoV) situation reports.https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed April 6 2020."},{"issue":"2","key":"e_1_2_10_3_1","first-page":"145","article-title":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID\u201019) in China","volume":"41","author":"Novel CPERE.","year":"2020","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa329"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1637-5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"key":"e_1_2_10_7_1","first-page":"520","article-title":"Application status of antihypertensive drugs in patients with hypertension in southwest China","volume":"4","author":"Zhang D","year":"2020","journal-title":"Chin J Epidemiol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu086"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2016.05.012"},{"key":"e_1_2_10_10_1","unstructured":"Team RC. R:A language and environment for statistical computing.Published online2013."},{"key":"e_1_2_10_11_1","first-page":"14","article-title":"RStudio: integrated development for R","volume":"42","author":"Team Rs.","year":"2015","journal-title":"RStudio Inc Boston MA URL Httpwww Rstudio Com."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3207"},{"key":"e_1_2_10_13_1","unstructured":"Drawing Survival Curves using \u201cggplot2.\u201dhttps:\/\/rpkgs.datanovia.com\/survminer\/index.html. Accessed April 6 2020."},{"key":"e_1_2_10_14_1","unstructured":"TherneauTTherneau\/Survival.; 2020.https:\/\/github.com\/therneau\/survival. Accessed April 6 2020."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.058"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa235"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753944715597623"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-017-0044-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4260"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221248"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0771-3"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa041"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_10_25_1","first-page":"1769","article-title":"COVID\u201019 and angiotensin\u2010converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","volume":"323","author":"Patel AB","year":"2020","journal-title":"JAMA"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.26315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.26315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.26315","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.26315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T14:25:01Z","timestamp":1693578301000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.26315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/jmv.26315"],"URL":"https:\/\/doi.org\/10.1002\/jmv.26315","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]},"assertion":[{"value":"2020-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}